We are live on ! Find out more
BIB icon

ProShares Ultra NASDAQ Biotechnology

7 hedge funds and large institutions have $2.52M invested in ProShares Ultra NASDAQ Biotechnology in 2013 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

38% more capital invested

Capital invested by funds: $1.82M → $2.52M (+$696K)

13% less funds holding

Funds holding: 87 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
7
Holders Change
-1
Holders Change %
-12.5%
% of All Funds
0.23%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
4
Reduced
1
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
LPL Financial
1
LPL Financial
California
$1.8M +$646K +22,320 +61%
PCM
2
Prelude Capital Management
New York
$464K +$413K +14,248 New
GT
3
Glenmede Trust
Pennsylvania
$123K +$23.2K +800 +27%
Creative Planning
4
Creative Planning
Kansas
$55K +$25.5K +880 +110%
U
5
UBS
Switzerland
$36K -$45.1K -1,556 -58%
AIG
6
American International Group
New York
$31.8K +$11.5K +396 +68%
S
7
SignatureFD
Georgia
$11K +$9.85K +340 New
Susquehanna International Group
8
Susquehanna International Group
Pennsylvania
-$805K -35,396 Closed
Bank of America
9
Bank of America
North Carolina
-$23K -1,000 Closed
CA
10
CapWealth Advisors
Tennessee
-$1K -56 Closed

BIB Hedge Fund Activity: Q3 2013 in Review

7 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2013, worth a combined $2.52M — up 38% from $1.82M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of BIB and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 4 added.

The largest buyer was LPL Financial, adding an estimated $646K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $805K sold.

  • 7 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2013, down from 8 in Q2 2013.
  • Funds reported $2.52M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2013, up 38% quarter-over-quarter.
  • 2 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2013 and 3 closed out, a net change of -1 holder.
  • The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2013 was LPL Financial, an estimated $646K added.
  • The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2013 was Susquehanna International Group, an estimated $805K sold.

Based on aggregated 13F filings for Q3 2013.